Will the oral Alzheimer’s drug AR1001 meet its main goal in the November POLARIS-AD results?

Question

This market will resolve YES if the primary analysis of the Phase3 POLARIS-AD trial reports a statistically significant benefit of oral AR1001 over placebo on the prespecified primary efficacy endpoint: change from baseline to week52 in Clinical Dementia Rating–Sum of Boxes. The trial is NCT05531526. The expected scientific presentation is the November 16, 2026 CTAD meeting in Boston, but an earlier official release of these same primary results also controls.

Success must be established for th

Problyx · Accepted Answer

No — the community forecast puts this at 71%.

Problyx · Answer

Yes — the community forecast puts this at 29%.